With Medley buy, Sanofi grabs Latin lead

It's official: Sanofi-Aventis is buying Medley, the big Brazilian generics maker. The $660 million deal will make Sanofi the biggest generics manufacturer in Latin America. And it adds yet another emerging-markets deal to the French company's recent series. "Medley constitutes a unique opportunity for Sanofi-aventis to build a strong and integrated platform for sustained profitable growth in Brazil and Latin America," the company said in a release.

With Medley's 127 generic products, Sanofi will boast a 12 percent market share in Brazil after the deal. Its share of the Mexican market--now that it's bought Laboratorios Kendrick--comes to some 15 percent. Brazil's generics market alone is expected to grow at a 20 percent annual rate over the next several years.

Like other Big Pharmas, Sanofi is gearing up for generic competition for its biggest revenue-drivers over the next several years. But unlike some of its rivals, Sanofi has opted out of the mega-merger and focused on small, strategic deals instead. The company has been focusing particularly on generics makers with a strong presence in emerging markets, where drug sales are forecast to grow at a much higher rate than in major industrialized nations such as the U.S.

- read Sanofi's release
- see the article in the Wall Street Journal

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.